KCT0009622尚未招募Unknown
A Randomized, Assessor-blinded, Controlled, Parallel, Prospective, Investigator's Clinical Trial to Evaluate the Efficacy and Safety of Electroacupuncture and Its Cotreatment with Electronic Moxibustion for Dry eye syndrome
aju Dongshin University Korean Medicine Hospital0 个研究点目标入组 45 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 70(Year)（—）
- 性别
- All
入选标准
- •Participants should meet all of the following criteria:
- •(1) Male or female patients aged 19-70 at the screening visit.
- •(2) Patients with ocular surface disease index (OSDI) score of =13.
- •(3) Patients with tear film break-up time (TFBUT) of = 10 seconds.
- •(4) Patients who can read and write Korean and voluntarily submitted written consent with their signature.
排除标准
- •Participants who have any of the following criteria are not eligible to participate in this study:
- •(1) Patients with dry eye syndrome caused by eyelids or eyelashes.
- •(2) Patients with Irritated eye caused by acute inflammation arising from the eyelid, eyeball, or ocular appendage.
- •(3) Patients who wore contact lenses within the recent 2 weeks or who have to wear contact lenses during the trial period.
- •(4) Patients who had an operation to the anterior segment of the eye or operation via the anterior eye including cataract or LASIK within recent 3 months.
- •(5) Patients who used anti-inflammatory drops, including cyclosporine, corticosteroids, or autoserotherapy, directly to the eye, within recent 2 weeks.
- •(6) Patients who are diagnosed with vitamin A deficiency.
- •(7) Patients who have difficulty in blink due to facial palsy.
- •(8) Patients who received punctal plug or punctal occlusion.
- •(9) Patients who have damages caused by injury of the eyeball or ocular appendage.
- •(10) Patients who have secondary dry eye syndrome due to scarring caused by irradiation, alkali burn, Stevens-Johnson syndrome, or cicatrical pemphigoid.
- •(11) Patients who are receiving treatments for allergic ocular conditions or viral conjunctivitis.
- •(12) Patients whose intraocular pressure is more than 25 mmHg in a single eye or both eyes or who are diagnosed with glaucoma.
- •(13) Patients who have active ocular infections including anterior uveitis or anterior blepharitis.
- •(14) Patients taking systemic corticosteroids or immunosuppressants.
- •(15) Patients who have an implant in the body that is unsuitable for acupuncture treatment, including pacemaker and implantable defibrillator, or are sensitive to electroacupuncture treatment.
- •(16) Pregnant, lactating women, or women planning pregnancy.
- •(17) Others whom investigators determined ineligible.
研究者
相似试验
进行中（未招募）
1 期
A randomised, controlled, assessor-blind, parallel groups, multinational,multicentre trial assessing the dose-response relationship of FE 999049in controlled ovarian stimulation in women undergoing an assistedreproductive technology programmeMedDRA version: 14.0Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertilityEUCTR2011-000633-36-ESFerring Pharmaceuticals A/S330
进行中（未招募）
1 期
MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycleInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleCTIS2022-500308-23-00Ferring Pharmaceuticals A/S151
进行中（未招募）
1 期
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeInfertilityEUCTR2013-001669-17-PLFerring Pharmaceuticals A/S1,350
进行中（未招募）
1 期
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeMedDRA version: 14.1Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertilityEUCTR2013-001669-17-ESFerring Pharmaceuticals A/S1,350
招募中
1 期
A trial to compare the ovarian response of REKOVELLE and GONAL-F in conventional dosing in women undergoing controlled ovarian stimulatioInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleMedDRA version: 20.0Level: PTClassification code 10021928Term: Infertility femaleSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2021-001785-38-ATFerring Pharmaceuticals A/S300